Search the Newsreel

Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX)

ImmunityBio (NASDAQ: IBRX) reported record Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase, and $94.8 million for the first half of 2026. Despite this revenue growth, the company experienced a higher GAAP net loss of $230.4 million in Q2 and …

FDA Sets Jan. 6 Target Date for ImmunityBio's ANKTIVA Review

Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (NASDAQ:IBRX) securities who bought shares prior to January 19, 2026, and continue to hold them. The investigation aims to determine if ImmunityBio and its officers engaged in corporate …

Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America

Bank of America Corporation has reported a beneficial ownership of 857,318 shares of Inhibrx Biosciences (INBX) common stock, which represents 5.9% of the class. This ownership is held through various affiliated entities, including BofA Securities, Inc., Bank of America, N.A., Merrill Lynch International, Merrill …

ImmunityBio (IBRX) Could Be 45% Undervalued On UAE ANKTIVA Approval

ImmunityBio (IBRX) has received marketing authorization for ANKTIVA in the UAE for two cancer indications, expanding its global footprint. Despite a recent share price pullback, the company is considered 45% undervalued, with a fair value of $13 compared to its last close of $7.17. …

IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease

ImmunityBio (IBRX) stock jumped nearly 8% after the UAE granted its cancer immunotherapy, Anktiva, its broadest approval yet for bladder and metastatic lung cancer. This approval covers a wider range of bladder cancer patients than currently allowed in the U.S. and follows founder Patrick …

ImmunityBio receives UAE marketing authorizations for ANKTIVA across NMIBC and NSCLC

ImmunityBio (IBRX) has been granted marketing authorization in the UAE for its cancer drug ANKTIVA for two indications: BCG-unresponsive NMIBC and checkpoint-refractory metastatic NSCLC. This expands ANKTIVA's approvals to 34 countries, with the NMIBC approval being the first worldwide to cover CIS with/without papillary …

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

ImmunityBio's ANKTIVA has received its broadest approval yet in the UAE for non-muscle invasive bladder cancer (NMIBC), covering the entire disease spectrum, and also for metastatic non-small cell lung cancer (NSCLC). This approval marks the fifth jurisdiction to greenlight ANKTIVA, expanding its global reach …

ImmunityBio Gains After UAE Approves ANKTIVA for Bladder and Lung Cancer Treatments

ImmunityBio (NASDAQ:IBRX) shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two cancer indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's international reach to 34 countries and is a significant milestone in …

Inhibrx Biosciences Inc (INBX) Institutional Confidence

The article analyzes the institutional confidence score for Inhibrx Biosciences Inc (INBX), which currently stands at 7.00, placing it 80th in its industry. Institutional shareholding has increased to 84.51%, with Andreas Halvorsen being the largest shareholder. The report also lists other significant institutional shareholders …

ImmunityBio stock jumps on UAE drug approval for ANKTIVA

ImmunityBio's shares rose 7.5% after the United Arab Emirates approved its drug ANKTIVA for two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's global regulatory footprint to 34 countries and is the first worldwide approval for …

Dow, S&P 500, Nasdaq Futures Rise As Investors Shrug Off Fed Hold, Big Tech Earnings: IBRX, MSFT, SOFI, META In Focus

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

ImmunityBio announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has granted Marketing Authorization for ANKTIVA across two indications: BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This marks the fifth regulatory approval for ANKTIVA …

Inhibrx Biosciences (INBX) Expands Its Credit Facility, Is The Valuation Risk Priced In?

Inhibrx Biosciences (INBX) recently expanded its credit facility to $500 million, leading to a reassessment of its valuation by investors, despite a strong year-to-date return. The company's high price-to-book ratio of 55.6x, compared to an industry average of 2.4x, reflects its negative equity and …

Inhibrx Biosciences Market Sentiment

The article provides a market sentiment overview for Inhibrx Biosciences (INBX), detailing analyst consensus, short interest, and recent analyst actions. Key signals indicate a "Buy" consensus from analysts with a significant upside on the price target, alongside a high short interest percentage. The analyst …

Immunitybio Inc (IBRX) Institutional Confidence

Immunitybio Inc (IBRX) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 20.71%, marking a 32.91% increase quarter-over-quarter. Paul Tudor Jones is the largest institutional shareholder, holding 557.67K shares.

ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by ImmunityBio, Inc. (NASDAQ:IBRX). The firm is encouraging investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact them to assist with the investigation. The investigation …

INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800

This article provides a comprehensive stock analysis of Inhibrx Biosciences Inc (INBX), highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. Despite a predicted medium-term downtrend, multiple analysts rate it as "Buy" with a high …

Inhibrx Biosciences, Inc. $INBX Shares Bought by SummitTX Capital L.P.

SummitTX Capital L.P. significantly increased its stake in Inhibrx Biosciences (NASDAQ:INBX) by 66.3% during the first quarter, now owning 137,821 shares valued at approximately $9.3 million. Other institutional investors also adjusted their holdings, with institutional investors and hedge funds collectively owning 82.46% of the …

IBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conference

ImmunityBio (IBRX) stock saw an overnight rise as retail traders anticipate announcements regarding the company's global expansion and partnerships at the upcoming BTIG Virtual Biotechnology Conference. Despite a recent dip, investor chatter highlights expectations for significant updates, especially concerning ImmunityBio's Anktiva immunotherapy, its NK-cell …

Inhibrx Biosciences Inc (INBX) Cash Flow

This article provides a comprehensive overview of Inhibrx Biosciences Inc's (INBX) cash flow statement, breaking down quarterly and annual data for operating, investing, and financing activities. It features detailed financial figures for various cash flow components, including net income, capital expenditures, and changes in …

Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX

Inhibrx Biosciences, Inc. (NASDAQ: INBX) generated $1.30 million USD in revenue last year, primarily from its Biologic Therapeutic segment. This represents a significant increase from the previous year's $200,000 USD. The United States was the company's largest contributor to revenue.

Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Inhibrx Biosciences Inc (INBX), listing major shareholders and their respective proportions. It also presents institutional shareholding trends over several quarters and highlights shareholder activity, including changes in holdings for key investors. Additionally, the article includes a section …

ImmunityBio says it is ‘incredibly committed’ to Dunkirk

ImmunityBio affirms its strong commitment to its Dunkirk, NY facility, which it leased after Athenex's bankruptcy. The company is investing significantly in renovations to transform the site into a pharmaceutical manufacturing plant, with operations expected by 2028. This commitment follows FDA approval for their …

ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts

ImmunityBio has partnered with Biopharma and Cigalah to launch its immunotherapy Anktiva in Saudi Arabia, with aspirations to expand across the broader Middle East and North Africa region. The company also established a new unit in Saudi Arabia to support distribution and commercialization, following …

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing allegations against ImmunityBio, Inc. (IBRX). The firm is encouraging shareholders who purchased ImmunityBio securities before January 19, 2026, and continue to hold them, to assist with the investigation. The firm operates …

Does Inhibrx Biosciences' (INBX) Expanded Credit Facility Quietly Redefine Its Risk‑Reward Profile?

Inhibrx Biosciences expanded its credit facility to $500.0 million with Oxford Finance, including an immediate $100.0 million Term C Loan. This move reduces short-term financing pressure and offers management more flexibility for trials, but also introduces higher leverage and financial risk. The company's investment …

ImmunityBio: Revisiting My Bearish Call After A 250% Rise (Upgrade) (NASDAQ:IBRX)

ImmunityBio (IBRX) receives a cautious buy rating from an analyst who previously held a bearish stance, following a 250% stock rise. The upgrade is driven by Anktiva's strong efficacy in NMIBC and its potential in broader oncology indications, with significant future revenue reflected in …

ImmunityBio (IBRX) Could Be 41% Below Fair Value After Anktiva Optimism

ImmunityBio (IBRX) has seen significant share gains due to investor optimism surrounding its bladder cancer therapy, Anktiva. Despite recent slight cooling in trading, the stock is considered 40.9% undervalued with a fair value of $13 per share, compared to its last close of $7.68. …

ImmunityBio (NASDAQ:IBRX) stock faces July 24 warrant-expiry test after Friday rebound

ImmunityBio (NASDAQ:IBRX) faces a warrant expiry test on July 24, with up to 6.4 million new shares potentially entering the market from 2023 warrants. These warrants, with an exercise price of $3.2946, were deeply in the money at Friday's closing price of $7.68. Full …

Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million

Inhibrx Biosciences has expanded its loan facility with Oxford Finance to $500 million through a second amendment to their agreement. This expansion includes a new tranche of up to $325 million, with $100 million funded immediately as a Term C Loan and an additional …

ImmunityBio (IBRX) Stock Looks Below Fair Value While Book Value Stays Weak

ImmunityBio (IBRX) has seen a significant 268.8% increase year-to-date, prompting a debate on its valuation. Simply Wall St's analysis indicates a mixed valuation, not clearly cheap nor expensive, with a negative Price-to-Book ratio due to losses. The future performance hinges on the commercial success …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by ImmunityBio, Inc. (IBRX) and certain officers/directors. Investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, are encouraged to join the investigation. The law firm represents investors …

Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit

Inhibrx Biosciences has significantly expanded its credit facility with Oxford Finance to an aggregate principal amount of up to $500 million, including an immediate $100 million Term C Loan and potential additional Term D Loans of $225 million. This expansion is outlined in an …

Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants

Inhibrx Biosciences expanded its senior secured credit facility with Oxford Finance and other lenders to up to $500 million, immediately drawing $100 million. The company also issued warrants for 21,457 shares to the lenders and pledged its equity in Poplar Therapeutics as collateral. These …

Press Release: Inhibrx Announces Amended Loan Agreement With Oxford Finance, Expanding Total Facility to $500.0 Million

Inhibrx has announced an amended loan agreement with Oxford Finance, increasing its total debt facility from $200.0 million to $500.0 million. This expanded financing is expected to provide greater financial flexibility as Inhibrx approaches potential commercialization for its drug candidates. The agreement also adjusts …